Shots:

• The P-ll SERENITY study involves the assessing of Mirikizumab (200mg- 600mg- 1000mg) vs PBO in patients in the ratio of 2:1:1:2 with moderately to severely active CD. The P-II study includes 12wks. induction period and 40wks. continued treatment period- evaluating the safety and efficacy of multiple dosing regimens and two methods of administration @52wks.
• Result: @52wks. ~60% achieved endoscopic responses (58.5% in IV dosing group and 58.7% in the SC group) while 45% + achieved PRO remission (46.3% in the IV group and 45.6% in the SC group)- presented at UEG Week 2020
• Mirikizumab is a humanized IgG4 mAb that binds to the P19 subunit of interleukin 23 and being studied for the treatment of immune diseases- including psoriasis- UC- & CD
  
   ­ Ref: PRNewswire | Image: Bless Ayurveda